Tiotropium Respimat Inhaler and the Risk of Death in COPD

Wise R. A., Anzueto A., Cotton D., Dahl R., Devins T., Disse B., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.369, no.16, pp.1491-1501, 2013 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 369 Issue: 16
  • Publication Date: 2013
  • Doi Number: 10.1056/nejmoa1303342
  • Journal Name: NEW ENGLAND JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1491-1501
  • Ankara University Affiliated: No

Abstract

BackgroundTiotropium delivered at a dose of 5 g with the Respimat inhaler showed efficacy similar to that of 18 g of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo.